NGENF News and Press, NervGen Pharma Corp From 05/15/23

2023-05-15 12:27:35 ET NervGen Pharma press release ( OTCQX:NGENF ): Q1 GAAP EPS of -$0.08. For further details see: NervGen Pharma GAAP EPS of -$0.08

Phase 1 clinical trial dosing completed Phase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023 Cash and investments of $18.0 million as of March 31, 2023 Vancouver, British Columbia--(Newsfile Corp. - May 15, 202...

Phase 1b/2a trial expected to commence in Q3 2023 First readout anticipated in 2024 Vancouver, British Columbia--(Newsfile Corp. - April 13, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innov...

2023-04-10 09:13:30 ET NervGen Pharma ( OTCQX:NGENF ) has announced the appointment of Mr. Michael Kelly to the position of President & CEO effective April 10, 2023. Mr. Kelly has also been appointed as a member of NervGen's Board of Directors. Mr. Kelly currently serv...

Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointme...

2023-03-30 09:36:32 ET NervGen Pharma press release ( OTCQX:NGENF ): FY GAAP EPS of -$0.39. NervGen had cash and investments of $22.5 million as of December 31, 2022, Research and development expenses were $16.6 million for the year ended December 31, 2022, compared to $6....

Equity proceeds of CA$22M+ raised during 2022 fiscal year Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoing Phase 1b/2a clinical trial of NVG-291 to include individuals with chronic and subacute spinal cord injuries Vancouver, Briti...

Completed NVG-291 dosing of subjects in Phase 1 clinical trial Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023 NVG-291 has been demonstrated in preclinical studies to promote repair mechanisms in the nervous system, including axonal regen...

Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US...

Canada's NervGen Pharma ( OTCQX:NGENF ) said it granted 400K incentive stock options to its directors. The stock options are exercisable at a price of C$1.74 per share for five years. The company noted all options were granted in accordance with the policies of the TSX...